<?xml version="1.0" encoding="UTF-8"?>
<p>Across all patients, 14 (20.3%) and 25 (36.2%) patients permanently and temporarily, respectively, discontinued study treatments (glasdegib and/or cytarabine/daunorubicin) due to AEs; 5 (7.2%) patients had dose reductions due to AEs and 35 (50.7%) patients reported serious AEs (SAEs). The most frequently reported SAEs (â‰¥5% of patients) were febrile neutropenia, sepsis, and pneumonia, and all other SAEs were reported by no more than two patients.</p>
